Introduction
Non-Hodgkin's lymphoma (NHL) is the second most frequent malignancy in patients with acquired immunodeficiency syndrome (AIDS). More than 90% of human immunodeficiency virus (HIV)-associated NHL is derived from B cells and the majority is of high grade. Extranodal presentation is more common in HIVseropositive patients and occurs in 70 to 80% of cases.
frequently in patients infected with HIV. 4 HIV-associated PBL is associated with an aggressive clinical course, poor prognosis, and short survival even in the era of highly active antiretroviral therapy (HAART).
5,6
We report a patient who developed an aggressive oral PBL as primary manifestation of AIDS.
Review of the Literature with Differential Diagnosis
PBL was first described in HIV-seropositive subjects by Delecluse et al and typically involves the oral cavity, 4 especially the jaw and the palate, and accounts for 2.6% of all NHLs in this population. 7 However, this rare neoplasm has been described in other sites such as lymph nodes, subcutaneous soft tissue, liver, bones, and anorectum. 8 A small number of cases have been reported in the medical literature, with the majority being case reports or small case series. 9 Ninety-two percent of oral PBL cases described in the medical literature were patients infected with HIV.
10,11
Besides the PBLs, other subtypes of B-cell NHLs may involve the oral cavity, including DLBCL and the Burkitt lymphoma. The differential diagnosis of large oral tumor lesions in patients with AIDs includes infections (intraoral tissue abscesses) and other malignant clinical entities, different from NHL. Infectious diseases that can involve the oral cavity include odontogenic abscesses caused by the oral microflora bacteria and oral lesions caused by fungi, especially Histoplasma capsulatum. Malignancies include Kaposi sarcoma of the oral cavity as initial and sole manifestation or associated with other mucocutaneous lesions, primary squamous cell carcinoma related with human papillomavirus infection, and metastatic lesions.
Case Report
A 39-year-old man with a history of intravenous drug abuse was admitted to our HIV/AIDS Department with a 1-month history of mild fever, weight loss, and night sweats. He presented with oral pain and odynophagia and dysphagia. On physical examination, the only remarkable finding was a large, nonfluctuant, and ulcerative mass, including dental pieces, with areas of necrosis, which involved the hard palate and the gingiva with a painful swelling over the right upper jaw. The lesion increased rapidly in size within the previous month (►Figs. 1 and 2). No peripheral cervical adenopathies were detected. Significant laboratory findings showed hemoglobin 11.30 g%, hematocrit 34%, white blood cells 3,300/mm 3 , platelets 39,000/mm 3 , erythrocyte sedimentation rate 78 mm/h, lactate dehydrogenase (LDH) 662 U/L, and alkaline phosphatase 130 IU/L. Renal and liver function were normal. A rapid enzymelinked immunosorbent assay (ELISA) for HIV was positive; HIV diagnosis was confirmed by fourth-generation ELISA and Western blot. Hepatitis C antibodies were also positive. The CD4 T-lymphocyte count was 57 cells/µL (8%) and the plasma viral load was 93,557 copies/mL log 10 5.0.
A computed tomography (CT) scan of the maxillofacial area revealed a large and heterogeneous mass with areas of necrosis involving the upper right gingival and the right hard palate with bone erosion of the upper jaw (►Figs. 3 and 4). A presumptive diagnosis of primary NHL of the oral cavity associated with AIDS was made and an incisional biopsy was performed.
The histopathologic examination of the biopsy smears showed a diffuse proliferation of atypical lymphoid cells with extensive areas of necrosis of the oral mucosa. The atypical cells contained large polygonal plasmablastic cells with abundant basophilic cytoplasm and large and excentric nuclei with a prominent central nucleoli associated with marked mitotic and apoptotic findings (►Fig. 5). Immunohistochemical examination revealed that the majority of tumor cells expressed the plasma cells markers CD138, VS38c, and MUM-1 and were negative for CD3, CD20, CD45, Bcl2, and Bcl6 (►Fig. 6). The Ki67 index was nearly 80%, revealing a high proliferation rate. A bone marrow biopsy was negative for neoplastic infiltration. A CT scan of the chest, abdomen, and pelvis did not show any abnormal findings. The histologic morphology and the plasma cell immunophenotype established the final diagnosis of primary PBL of the oral cavity. The Epstein-Barr (EBV) virus genome was detected in the atypical tumor cells by in situ hybridization (ISH; ►Fig. 7). Polymerase chain reaction (PCR) was positive for human herpes virus 8 (HHV-8) RNA in the tumor cells.
After a partial response to the first cycle of chemotherapy based on CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisolone) plus preventive intrathecal chemotherapy (methotrexate and cytarabine) plus HAART (abacavir plus lamivudine plus efavirenz), the neoplasm relapsed, with a large, ulcerative, and necrotizing lesion that involved both hard and soft palate, the gingiva, and the upper maxilla and that took up the oral cavity. The lesion did not respond to the two following cycles of chemotherapy. Two months later, the patient died due to the lymphoma progression and sepsis with multiorgan failure.
Discussion
Patient with HIV infection are at increased risk to develop NHL. These lymphomas are characterized by rapid progression, frequent extranodal initial manifestation, and a poor outcome.
5,6
PBL was first described in HIV-seropositive subjects by Delecluse et al, 4 and it typically involves the oral cavity, especially the jaw and the palate, and accounts for 2.6% of all NHLs in this population. 7 However, this rare neoplasm has been described in other sites such as lymph nodes, subcutaneous soft tissue, liver, bones, and anorectum. 8 A small number of cases have been reported in the medical literature, with the majority as case reports or small case series. 9 Ninetytwo percent of oral PBL cases described in the medical literature were HIV-infected patients.
10,11
PBL is included in the World Health Organization classification as a subtype of lymphoma described most frequently in HIV-infected patients. 6 This lymphoma is characterized by an unusual immunophenotype with negative CD20 and a predominant plasma cell differentiation, expressing markers such as CD38, CD138, and MUM1 protein. PBL immunophenotype is similar to myeloma; however, using genomic profiling, PBL seems closer to DLBCL.
12
Clinically, the most significant characteristic of PBL in patients with AIDS is the compromise of the oral cavity, including the hard palate, the gingiva, and the jaw, as occurred in our patient, who had large masses as the unique clinical finding. Gingival involvement is characteristic in HIVseropositive patients, whereas the tongue involvement is more frequent in immunocompetent patients. PBL of the oral cavity always involves the hard palate.
13
Histopathologic characteristics of PBL include the advanced stage of the neoplasm at diagnosis, elevated LDH levels, and a very high proliferation index (Ki67 level) more than 80%, as we saw in our patient.
5 Histologic differential diagnosis of oral PBL includes Burkitt lymphoma of the oral cavity with plasmablastic differentiation, anaplastic subtypes of DLBCL, and poorly differentiated oral carcinomas.
5
EBV is strongly associated with the pathogenesis of PBL in patients with AIDS, and EBV expression by atypical cells is frequent in AIDS-associated PBL (70% of cases).
14 The presence of EBV genome can be detected in atypical cells by two techniques, immunohistochemistry for latent membrane protein-1 and ISH for Epstein-Barr encoding region (EBERs-1 RNA). Additionally, detection of HHV-8 DNA was also positive by PCR in our patient. PBL in patients with AIDS is generally associated with a poor prognosis. The most common causes for this poor prognosis include the regular relapsing evolution of PBL, which can be explained by the severe immunosuppression associated with advanced HIV/AIDS disease, and the chemoresistance of PBL, which explains the most frequent cause of death (lymphoma progression, as we observed in our patient). Development of infectious complications is the second most common cause of death in these patients.
11,13
Treatment of PBL is similar to other aggressive lymphomas; CHOP or CHOP-like regimens are the most common therapeutic alternatives. Although some physicians use regimens more intensive than CHOP, the role of such therapy is unclear.
5,12
Castillo et al analyzed retrospectively 70 patients with HIV-associated PBL treated with chemotherapy. 5 In this series, the mean CD4 þ T-cell count was 165 cells/µL, and the overall response rate to chemotherapy was 77%, but only 46% of the patients presented complete response. The overall survival rate was 14 months, and 72% of patients died from lymphoma progression, as in our case. In this study, the use of regimens more intensive than CHOP were not associated with a better survival.
Final Comments
PBL is an aggressive subtype of DLBCL with distinct histopathologic features, pathogenic viral associations, and outcome. The association between PBL and HIV infection has been well demonstrated, with a high prevalence in the oral cavity.
8,9,15
In summary, PBL should be included in the differential diagnosis of large masses involving the oral cavity. The HIV serologic status should be evaluated in all patients with PBL of the oral cavity or extraoral sites.
